Septerna (NASDAQ:SEPN) Stock Price Down 8% - Time to Sell?
Septerna's stock (NASDAQ:SEPN) recently dropped 8% to $40.41, with trading volume significantly below its average. Despite this, analysts maintain a "Moderate Buy" rating with an average price target of $52.44, citing the company's beat on quarterly earnings expectations. However, insider selling of 72,828 shares worth approximately $2.68 million over the last quarter raises questions for potential investors.
SEPTERNA, INC. : JP MORGAN RAISES TARGET PRICE TO $48 FROM $38
J.P. Morgan has raised its target price for SEPTERNA, INC. (SEPN.O) to $48 from the previous $38. This update reflects the analyst's revised outlook on the company's valuation. The article states that this content solely reflects the author's opinion and is not investment advice.
4,211,659 Shares in Septerna, Inc. $SEPN Acquired by Trv Gp Vi LLC
Trv Gp Vi LLC has acquired over 4.2 million shares of Septerna, Inc. (NASDAQ:SEPN) valued at approximately $141 million, making it their largest portfolio holding with a 9.34% stake. This acquisition comes amidst positive analyst sentiment, with an average "Moderate Buy" rating and a price target of $51.33, and Septerna beating quarterly earnings expectations. However, some insiders have recently sold shares, though the company itself is a clinical-stage biotechnology firm focused on GPCR oral small molecule drug discovery.
Trv Gp V LLC Takes Position in Septerna, Inc. $SEPN
Trv Gp V LLC has acquired a significant new position in Septerna, Inc. (NASDAQ:SEPN) during the second quarter, making it their second-largest holding. Other institutional investors like BlackRock and Goldman Sachs have also increased their stakes, indicating growing institutional interest. Despite some insider selling, analysts maintain a "Moderate Buy" consensus for Septerna, which also exceeded revenue and EPS expectations in its latest quarterly report.
Septerna, Inc. (SEPN) Receives a Rating Update from a Top Analyst
Stifel Nicolaus analyst Alex Thompson CFA reiterated a Buy rating on Septerna, Inc. (SEPN) and set a $46.00 price target. This comes as corporate insider sentiment for SEPN is negative, with an increase in insider selling. The company recently reported Q2 revenue of $26.75 million and a GAAP net loss of $13.03 million.
37,700 Shares in Septerna, Inc. $SEPN Purchased by Renaissance Technologies LLC
Renaissance Technologies LLC has acquired a new stake of 37,700 shares in Septerna, Inc. (NASDAQ:SEPN) valued at $906,000. This comes as Septerna reported better-than-expected quarterly results and received positive sentiment from analysts, with a consensus "Moderate Buy" rating and an average price target of $51.33. Despite positive analyst outlooks and strong earnings, insiders have sold a significant number of shares recently.
Ra Capital Management sells $63.45m in Septerna stock
RA Capital Management, a major shareholder in Septerna Inc. (NASDAQ:SEPN), sold 1,493,000 shares of common stock for a total of $63.45 million on August 12, 2026. The sale occurred after Septerna's stock surged 280% over the past year, with shares trading at $42.50 during the transaction. Despite the sale, RA Capital Healthcare Fund and RA Capital Nexus Fund III still hold significant indirect stakes in Septerna.
Driehaus Capital Management (SEPN) discloses 4.43M-share Septerna stake in 13G/A
Driehaus Capital Management LLC has filed an amended Schedule 13G/A, reporting a beneficial ownership of 4,433,058 shares of Septerna, Inc. common stock, which represents 9.83% of the class. Driehaus holds shared voting and dispositive power over these shares, managed across numerous client accounts. The filing clarifies that no single underlying client is known to have rights to dividends or sale proceeds for more than 5% of Septerna's common stock.
Third Rock Ventures V, L.P. director sells $7.4m Septerna shares
Third Rock Ventures V, L.P., a significant shareholder and director of Septerna, Inc., sold 147,200 shares of the company's common stock for approximately $7.4 million on August 12, 2026. The sales were executed through a pre-arranged trading plan, with shares trading near their 52-week high, reflecting a 281% return over the past year. Following these transactions, Third Rock Ventures V, L.P. still directly holds over 6 million shares, while another entity, Third Rock Ventures VI, L.P., holds over 4 million shares indirectly.
Septerna (SEPN): RA Capital funds disclose sale of 1.49M common shares
RA Capital Healthcare Fund LP and RA Capital Nexus Fund III, L.P. reported the sale of 1,493,000 common shares of Septerna, Inc. (SEPN) on August 12, 2026, at a price of $42.50 per share. The sales were made by affiliated entities of RA Capital, with Peter Kolchinsky and Rajeev Shah disclaiming beneficial ownership beyond their pecuniary interests. Following these transactions, RA Capital's indirect holdings in Septerna stand at 725,443 shares.
Form 4: Third Rock Ventures reports acquisition/exercise transactions in SEPN
Third Rock Ventures V, L.P. reported insider transactions in Septerna, Inc. (SEPN) through a Form 4 filing, indicating sales of 147,200 shares at a weighted average price of $50.27 per share. These transactions, executed on August 12, 2026, were conducted under a Rule 10b5-1 trading plan. After these sales, Third Rock Ventures entities still hold a substantial number of SEPN shares, with Third Rock Ventures V, L.P. directly holding 6,068,391 shares and Third Rock Ventures VI, L.P. indirectly holding 4,211,659 shares.
RA Capital group (SEPN) discloses 11.8% Septerna stake and major block sales
RA Capital Management and its associated entities have disclosed a beneficial ownership of 11.8% in Septerna, Inc. (SEPN), totaling 5,525,324 shares. This updated filing, a Schedule 13D/A, details holdings across various funds and includes significant block sales made on August 12, 2026, where RA Capital Healthcare Fund and RA Capital Nexus Fund III each sold 746,500 shares at $42.50 per share. The report also outlines vested stock options held for RA Capital's benefit with specified exercise prices.
Price to sales forward of Septerna, Inc. – NASDAQ:SEPN
This article provides information about the "Price to sales forward" metric for Septerna, Inc. (NASDAQ: SEPN) as listed on TradingView. It indicates that the market was closed at the time of viewing, with no trades for the company. The content primarily consists of navigation links and disclaimers related to the TradingView platform.
Septerna (SEPN) President & COO exercises 25,000 options and sells shares under 10b5-1 plan
Septerna, Inc. President and COO Elizabeth Bhatt exercised 25,000 stock options on August 11, 2026, with exercise prices of $6.81 for 18,681 shares and $2.76 for 6,319 shares. On the same day, she sold all 25,000 Common Stock shares at $44.00 per share. This sale was conducted under a pre-arranged Rule 10b5-1 sales plan adopted on October 20, 2025.
Septerna president & COO Elizabeth Bhatt disposes of $1.1m in stock
Elizabeth Bhatt, President and COO of Septerna, Inc. (NASDAQ:SEPN), sold 25,000 shares of common stock for $1.1 million on August 11, 2026, after acquiring them through stock option exercises. These transactions were executed under a Rule 10b5-1 sales plan, leaving Bhatt with 174,209 directly owned shares and 144,562 stock options. The company's stock has seen significant returns, and analysts have recently issued mixed but generally optimistic updates on Septerna's drug pipeline.
Septerna, Inc. SEC Filing (Aug 12, 2026)
Septerna, Inc. has filed a Form 144 with the SEC on August 12, 2026, indicating a proposed sale of securities. The filing details the sale of 746,500 common shares acquired through an IPO on October 25, 2024, with an aggregate market value of $35,973,835.00, to be handled by BTIG LLC.
SEPN (SEPN) plans NASDAQ sale of 746,500 shares worth $35.97M
Septerna, Inc. (SEPN) has filed a Form 144 indicating its intent to sell 746,500 common shares on NASDAQ through broker BTIG LLC, with an aggregate market value of $35,973,835.00. These shares were acquired in two blocks in May and October 2024 through IPO settlement or private funding. The company currently has 46,676,947 common shares outstanding.
Does Septerna (SEPN) Pair Narrowing Losses With A Cash Runway That Truly Supports Its Pipeline Strategy?
Septerna, Inc. reported narrowing net losses and increased sales in Q2 2026, driven by a collaboration with Novo Nordisk. The company reiterated its cash runway into 2029, supporting its early-stage clinical pipeline. Despite positive financial updates, the article notes ongoing concerns regarding Septerna's valuation and potential risks from clinical data or partner momentum.
Septerna Inc stock hits all-time high at 50.0 USD By Investing.com
Septerna Inc (SEPN) stock has reached an all-time high of $50, currently trading at $49.47 with a market capitalization of $2.28 billion, reflecting a 326% increase over the past year. InvestingPro analysis suggests the stock is fairly valued, with significant momentum highlighted by a 71% year-to-date return. This comes amidst recent analyst updates on its drug candidate SEP-479, with H.C. Wainwright, Stifel, and Guggenheim adjusting price targets based on trial progress and competitive landscape.
H.C. Wainwright raises Septerna stock price target to $60 on SEP-479 progress
H.C. Wainwright increased its price target for Septerna Inc (NASDAQ:SEPN) to $60 from $40, maintaining a Buy rating, due to positive progress in the Phase 1 trial of SEP-479 for hypoparathyroidism. The drug shows a favorable pharmacokinetic profile supporting once-daily dosing, with full Phase 1 data expected in Q1 2027. This update aligns with other analysts like Stifel, Guggenheim, and Truist, who have also raised their price targets for Septerna based on the promising SEP-479 pipeline.
Septerna, Inc. Stock 12‑Month Price Target Raised to $47, Implies 21% Upside
Septerna, Inc.'s average 12-month price target has been increased from $45 to $47 by 9 analysts, with individual forecasts ranging from $38 to $60 per share. This new target suggests a potential upside of approximately 21% based on the August 10 closing price. The consensus rating for SEPN remains a "Buy" across 10 covering analysts.
Seer (SEPN) insiders plan sale of 29,000 shares after option exercise
Seer, Inc. (SEPN) has filed a Form 144 notice to allow the potential sale of 29,000 common shares by an affiliate, following an option exercise on August 11, 2026, valued at $1,126,650.00. The filing also disclosed a previous sale of 4,000 shares on July 15, 2026, under a Rule 10b5-1 plan for Elizabeth P. Bhatt, generating $135,974.00. Morgan Stanley Smith Barney LLC will handle the planned share sale.
Septerna, Inc. Stock 12‑Month Price Target Raised to $46.78, Implies 20% Upside
Analysts have raised Septerna, Inc.'s average 12-month price target from $45 to $47, with forecasts ranging from $38 to $60 per share. This new target implies a potential upside of approximately 21% from the August 10th closing price. The consensus rating from 10 analysts remains a "Buy," with no "Holds" or "Sells."
Raymond James Maintains Septerna(SEPN.US) With Buy Rating, Cuts Target Price to $49
Raymond James has reiterated its Buy rating for Septerna (SEPN.US) but has adjusted its price target downwards to $49. This indicates a continued positive outlook on the company's prospects despite a revision in the expected share price. Investors may see this as a signal that the firm believes Septerna still has significant upside potential.
Septerna (NASDAQ:SEPN) Stock Price Up 9% Following Earnings Beat
Septerna (NASDAQ:SEPN) shares rose 9% after reporting better-than-expected quarterly earnings, with an EPS of negative $0.29 against estimates of negative $0.43, and revenue of $26.75 million exceeding the $19.22 million consensus. Despite broad analyst positivity and a "Moderate Buy" consensus rating, the company remains unprofitable with negative net margins. Insider selling of 47,828 shares worth approximately $1.58 million has been noted in the last 90 days, even as institutional investors increased their positions.
Stifel raises Septerna stock price target to $49 on SEP-479 outlook
Stifel increased its price target for Septerna Inc (NASDAQ:SEPN) shares to $49 from $43, maintaining a Buy rating. This adjustment is based on an increased probability of success for their drug candidate SEP-479, a first-in-class oral PTH1R agonist for hypoparathyroidism. The company has also re-evaluated its development plans for SEP-631 following a competitor's setback.
Stifel raises Septerna stock price target to $49 on SEP-479 outlook
Stifel has increased its price target for Septerna Inc. (NASDAQ:SEPN) to $49 from $43, maintaining a Buy rating due to an improved outlook for SEP-479, a hypoparathyroidism drug. The firm raised the drug's probability of success to 50% from 33% based on positive preclinical data and strong market reception for similar treatments. Despite some developmental uncertainties with another drug, SEP-631, Septerna maintains a strong financial position, and other analysts like Guggenheim, H.C. Wainwright, Truist Securities, and Raymond James also hold positive outlooks on the company.
Guggenheim raises Septerna stock price target to $51 on pipeline progress
Guggenheim has increased its price target for Septerna Inc. (NASDAQ:SEPN) to $51 from $45, maintaining a Buy rating, due to pipeline progress and an increased probability of success for its drug candidate SEP-479. The company is also exploring new indications for SEP-631 and expects its current cash position to fund operations into at least 2029. This update follows several other analyst adjustments reflecting varied perspectives on Septerna's drug development and financial outlook.
Septerna (NASDAQ:SEPN) Hits New 1-Year High - Still a Buy?
Septerna (NASDAQ:SEPN) recently hit a new 52-week high of $40.65, trading around $38.26, significantly above its moving averages. The clinical-stage biotech reported better-than-expected quarterly earnings, with a loss of $0.19 per share against an anticipated $0.42 loss, and revenues of $26.52 million, exceeding estimates of $16.98 million. Despite this, the company remains unprofitable with a negative net margin, and analysts have a "Moderate Buy" consensus with an average price target of $45.89.
Septerna, Inc. (SEPN) Reports Q2 Loss, Beats Revenue Estimates
Septerna, Inc. (SEPN) reported a Q2 loss of $0.29 per share, beating the Zacks Consensus Estimate of a $0.48 loss and surpassing last year's $0.56 loss. The company's revenues for the quarter reached $26.75 million, significantly exceeding the Zacks Consensus Estimate by 30.07%. Despite outperforming the market year-to-date, Septerna currently holds a Zacks Rank #4 (Sell), suggesting potential underperformance in the near future.
Septerna Q2 Results: Sales surge 22,380% YoY to $26.746M
Septerna reported a significant revenue surge to $26.7 million in Q2 2026, primarily due to its collaboration with Novo Nordisk, a dramatic increase from $0.1 million in Q2 2025. The company also narrowed its net loss to $13.0 million and maintains a strong cash position of $516.5 million, expected to fund operations into 2029. Progress in its clinical pipeline includes promising Phase 1 data for SEP-479, supporting once-daily dosing for hypoparathyroidism, with full data anticipated in Q1 2027.
Earnings Flash (SEPN) Septerna, Inc. Reports Q2 Revenue $26.7M, vs. FactSet Est of $19.2M
Septerna, Inc. (SEPN) reported its second-quarter revenue of $26.7 million, significantly surpassing FactSet's estimate of $19.2 million. This financial news also notes that the company's Q2 loss per share narrowed to $0.29, compared to an estimated loss of $0.43. Septerna is a clinical-stage biotechnology company focused on developing oral small-molecule drugs targeting G protein-coupled receptors.
Septerna (NASDAQ:SEPN) Releases Earnings Results, Beats Expectations By $0.14 EPS
Septerna (NASDAQ:SEPN) announced its latest earnings results, reporting an adjusted loss of $0.29 per share, which beat analyst expectations by $0.14. The company's revenue also surpassed estimates, reaching $26.75 million against a consensus of $19.22 million. Despite strong financial performance and a "Moderate Buy" consensus rating from analysts, company insiders have sold a significant number of shares recently.
Price to book forward of Septerna, Inc. – NASDAQ:SEPN
The article focuses on the "Price to book forward" metric for Septerna, Inc. (NASDAQ: SEPN). It indicates that the company is listed on the Nasdaq Stock Market and provides information about its financial data, market status, and other related details through the TradingView platform.
Price to earnings forward of Septerna, Inc. – NASDAQ:SEPN
This article provides a link to the "Price to earnings forward" financial data for Septerna, Inc. (NASDAQ:SEPN) on TradingView. It highlights the company's stock information and links to various financial tools and community features on the platform. The content is primarily navigation and boilerplate information from the TradingView website.
ETFs Investing in Septerna, Inc. Stocks
This article lists various ETFs that currently hold stocks of Septerna, Inc. (SEPN). The ETFs are sorted by market value and include details such as issuer, management style, focus, expense ratio, and assets under management. The information aims to help investors find accessible and diversified opportunities in Septerna, Inc. through ETFs.
Septerna (NASDAQ:SEPN) SVP Sells $114,922.98 in Stock
Septerna (NASDAQ:SEPN) SVP Daniel Long sold 3,334 shares of the company's stock for $114,922.98 on August 3rd, 2026, reducing his ownership by 3.34% to 96,412 shares valued at approximately $3.32 million. The company's stock is trading near its 52-week high, with a market capitalization of $1.75 billion, and has exceeded recent quarterly earnings and revenue expectations despite remaining unprofitable. Analysts hold a "Moderate Buy" consensus rating with an average price target of $45.89.
Septerna (SEPN) SVP exercises options and sells 3,334 shares under plan
Daniel D. Long, SVP of Drug Discovery at Septerna (SEPN), exercised stock options for 3,334 shares of common stock at $2.76 per share and subsequently sold all 3,334 shares on August 3, 2026. The sales were executed in two blocks at weighted average prices of $33.9756 and $34.6805, respectively, as part of a pre-arranged Rule 10b5-1 sales plan adopted on March 20, 2026. This transaction resulted in an approximate pre-tax spread of $106K from the exercise and sale.
Septerna Inc stock hits all-time high at 38.21 USD
Septerna Inc.'s stock reached an all-time high of $38.21, reflecting a 221.8% increase over the past year and strong investor confidence, despite some InvestingPro analysis suggesting overvaluation. Analysts have a mixed but generally optimistic outlook, with price targets ranging from $40 to $60, based on positive clinical trial results and revised assumptions for its programs.
Septerna Inc stock hits all-time high at 38.21 USD By Investing.com
Septerna Inc. (SEPN) stock reached an all-time high of $38.21, reflecting a 221.8% increase over the past year and strong investor confidence. Despite being considered overvalued by some metrics, analysts maintain bullish price targets, with several firms reiterating Buy ratings and raising price targets based on promising trial results and pipeline developments. The company's market capitalization stands at $1.71 billion.
SEPN|Septerna Inc|Price:33.660|Chg%:-0.310
This article provides a comprehensive stock analysis of Septerna Inc (SEPN), highlighting its strong fundamentals, high growth potential, and fair valuation within the Biotechnology & Medical Research industry. The company, a clinical-stage biotechnology firm, is developing GPCR oral small-molecule drugs with a pipeline focused on endocrinology, immunology, inflammation, and metabolic diseases. Analysts currently rate SEPN as a "Buy" with a target price indicating significant upside potential.
Septerna Inc (SEPN) Institutional Confidence
Septerna Inc (SEPN) has an institutional shareholding score of 10.00, placing it first among 384 companies in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 106.37%, a 5.10% quarter-over-quarter increase. John Hussman is the largest institutional shareholder, holding 84.59K shares, which represents 0.23% of shares outstanding.
Septerna Inc (SEPN) Financial Health: Profitability & Balance Sheet Analysis
Septerna Inc (SEPN) currently holds a financial score of 8.65, positioning it at 35 out of 385 in the Biotechnology & Medical Research industry, reflecting a weak financial status but high operating efficiency. The company reported a significant year-over-year revenue increase of 12010.96% to $26.52 million and a net profit increase of 59.78%. Detailed data for cash and cash equivalents, total assets, total liabilities, free cash flow, total revenue, operating profit, and SG&A have not been fully disclosed yet.
SEPN|Septerna Inc|Price:35.017|Chg%:+1.407
Septerna Inc. (SEPN) is a clinical-stage biotechnology company focused on developing oral small-molecule drugs targeting G protein-coupled receptors (GPCRs) using its proprietary Native Complex Platform. The company's pipeline addresses endocrinology, immunology, inflammation, and metabolic diseases, and it aims to discover novel treatments for unmet medical needs. Key information includes its IPO date, executive team, and institutional shareholdings.
Septerna Inc (SEPN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article from TradingKey attempts to provide a revenue breakdown for Septerna Inc (SEPN), detailing its business segments, regional revenue, and profit contribution. However, the company has not yet disclosed the relevant financial data necessary for this analysis. Consequently, the report states that information regarding revenue by business and by region is currently unavailable.
Septerna Inc (SEPN) Valuation: PE, PB & Fair Value Analysis
Septerna Inc (SEPN) has a current valuation score of 8.48, placing it 126th out of 386 companies in the Biotechnology & Medical Research industry. The company's P/E ratio stands at -41.42, which is significantly below its recent high and slightly above its recent low. Key valuation metrics like P/B, P/S, and P/CF have not yet been disclosed by the company.
Septerna, Inc. Revenue Breakdown – NASDAQ:SEPN
This article provides a revenue breakdown for Septerna, Inc. (NASDAQ:SEPN). The company generated $45.95 million USD last year, with its G Protein-coupled Receptor segment being the top performer. All reported revenue was generated from the United States.
Septerna, Inc. (NASDAQ:SEPN) Receives Average Rating of "Moderate Buy" from Brokerages
Septerna, Inc. (NASDAQ:SEPN) has received an average "Moderate Buy" rating from brokerages, with an average 12-month price target of $45.89, exceeding its current stock price of $33.49. The company reported better-than-expected quarterly results, with a loss of $0.19 per share against an estimated $0.42 loss, and revenues of $26.52 million surpassing the $16.98 million expectation. Despite insider selling of shares worth approximately $1.47 million, institutional investors like Woodline Partners, Geode Capital, and JPMorgan have increased their holdings.
Septerna Inc (SEPN) Balance Sheet
This article provides detailed balance sheet information for Septerna Inc (SEPN), allowing users to evaluate the company's financial health, analyze fundamentals, and calculate key ratios. It breaks down quarterly and annual data for assets, liabilities, and shareholders' equity, including specifics like cash, receivables, fixed assets, debt, and retained earnings. The document also includes an FAQ section addressing important balance sheet metrics and definitions for assets, liabilities, and equity.
Septerna Inc (SEPN) Income Statement
This article provides the quarterly and annual income statements for Septerna Inc (SEPN), detailing its financial performance. It includes key figures such as total revenue, operating expenses, net income, and earnings per share, alongside year-over-year comparisons. The data from FY2023Q3 through FY2026Q1 allows investors to analyze the company's operational efficiency and profitability dynamics.
